8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A clinical breakdown of isotretinoin's compounding restrictions under federal law, the iPLEDGE REMS program, FDA enforcement history, and what the current label requires for prescribers and patients.
A detailed review of isotretinoin (Accutane) safety signals reported to the FDA Adverse Event Reporting System (FAERS), covering psychiatric events, IBD associations, teratogenicity monitoring through iPLEDGE, and what the post-market surveillance data mean for prescribers and patients.
Complete regulatory timeline of isotretinoin from its 1982 FDA approval through iPLEDGE implementation, generic entry, and ongoing post-market safety surveillance.
Current isotretinoin regulatory status in the United States, European Union, United Kingdom, Canada, Australia, and Brazil, including iPLEDGE and pregnancy-prevention rules.
A complete clinical reference covering every FDA label change, iPLEDGE revision, and post-market safety signal for isotretinoin from 2020 through 2026, with primary-source citations throughout.
A clinical review of isotretinoin's regulatory history, current FDA label requirements, iPLEDGE program updates, next-generation retinoid pipeline candidates, and post-market safety surveillance data.
A detailed comparison of how the FDA and EMA regulate isotretinoin, covering iPLEDGE vs Pregnancy Prevention Programme, label differences, post-market surveillance, and what each framework means for patients and prescribers.
A detailed look at isotretinoin's FDA approval history, patent expirations, product liability litigation, iPLEDGE regulatory requirements, and ongoing safety monitoring.